204 related articles for article (PubMed ID: 10895180)
1. Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
Fujiwara K
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():354-8. PubMed ID: 10895180
[No Abstract] [Full Text] [Related]
2. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases.
Fujiwara K; Yamauchi H; Yoshida T; Suzuki S; Oda T; Kohno I
Gynecol Oncol; 1998 Aug; 70(2):231-5. PubMed ID: 9740696
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
Markman M; Walker JL
J Clin Oncol; 2006 Feb; 24(6):988-94. PubMed ID: 16461779
[No Abstract] [Full Text] [Related]
4. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
5. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
Lentz SS; Miller BE; Kucera GL; Levine EA
Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
7. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
[TBL] [Abstract][Full Text] [Related]
8. The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction.
Rettenmaier MA; Gray CM; Lopez KL; Bechtol KA; Goldstein BH
Am J Obstet Gynecol; 2014 Feb; 210(2):e1-2. PubMed ID: 24184183
[TBL] [Abstract][Full Text] [Related]
9. Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
Oestreicher P
ONS Connect; 2007 Apr; 22(4):24-5. PubMed ID: 17477008
[No Abstract] [Full Text] [Related]
10. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Markman M
Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
[TBL] [Abstract][Full Text] [Related]
12. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal chemotherapy for ovarian cancer.
Anastasia P
Oncol Nurs Forum; 2012 Jul; 39(4):346-9. PubMed ID: 22750892
[No Abstract] [Full Text] [Related]
14. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
15. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
16. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
18. Role of chemotherapy in the management of epithelial ovarian cancer.
Reed NS; Sadozye AH
Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
Tummala MK; Alagarsamy S; McGuire WP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
